Guidelines for the management of myeloproliferative neoplasms
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Bang, Soo-Mee | - |
dc.contributor.author | Jang, Seongsoo | - |
dc.contributor.author | Jung, Chul Won | - |
dc.contributor.author | Kim, Hee-Jin | - |
dc.contributor.author | Kim, Ho Young | - |
dc.contributor.author | Kim, Soo-Jeong | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Won, Jong-Ho | - |
dc.date.accessioned | 2021-09-04T11:10:24Z | - |
dc.date.available | 2021-09-04T11:10:24Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2015-11 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92103 | - |
dc.description.abstract | Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new target for drug development. The JAK1/2 inhibitor, ruxolitinib, was the first JAK inhibitor approved for patients with intermediate-to high-risk myelofibrosis and its effects in improving symptoms and survival benefits were demonstrated by randomized controlled trials. In 2011, the Korean Society of Hematology MPN Working Party devised diagnostic and therapeutic guidelines for Korean MPN patients. Subsequently, other genetic mutations have been discovered and many kinds of new drugs are now under clinical investigation. In view of recent developments, we have revised the guidelines for the diagnosis and management of MPN based on published evidence and the experiences of the expert panel. Here we describe the epidemiology, new genetic mutations, and novel therapeutic options as well as diagnostic criteria and standard treatment strategies for MPN patients in Korea. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | LOW-DOSE ASPIRIN | - |
dc.subject | INTERNATIONAL WORKING GROUP | - |
dc.subject | PROGNOSTIC SCORING SYSTEM | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | REVISED RESPONSE CRITERIA | - |
dc.subject | POST-POLYCYTHEMIA VERA | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject | PRIMARY MYELOFIBROSIS | - |
dc.subject | ALLELE BURDEN | - |
dc.title | Guidelines for the management of myeloproliferative neoplasms | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.3904/kjim.2015.30.6.771 | - |
dc.identifier.scopusid | 2-s2.0-84947075911 | - |
dc.identifier.wosid | 000366667300003 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.30, no.6, pp.771 - 788 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 30 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 771 | - |
dc.citation.endPage | 788 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | PROGNOSTIC SCORING SYSTEM | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | REVISED RESPONSE CRITERIA | - |
dc.subject.keywordPlus | POST-POLYCYTHEMIA VERA | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | ESSENTIAL THROMBOCYTHEMIA | - |
dc.subject.keywordPlus | PRIMARY MYELOFIBROSIS | - |
dc.subject.keywordPlus | ALLELE BURDEN | - |
dc.subject.keywordPlus | LOW-DOSE ASPIRIN | - |
dc.subject.keywordPlus | INTERNATIONAL WORKING GROUP | - |
dc.subject.keywordAuthor | Polycythemia vera | - |
dc.subject.keywordAuthor | Thrombocythemia, essential | - |
dc.subject.keywordAuthor | Primary myelofibrosis | - |
dc.subject.keywordAuthor | Practice guideline | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.